A Phase 1 Clinical Trial of Personalized, Adoptive Cellular Immunotherapy Targeting Patient-specific Neoplastic Stem Cell Neoantigens (PACTN) in Patients With Myelodysplastic Syndromes (MDS)
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2018
Price : $35 *
At a glance
- Drugs Myelodysplastic-stem-cell-neoantigens-targeting-autologous-T-cell-therapy (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms PACTN
- Sponsors PersImmune
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 17 Sep 2018 Planned number of patients changed from 9 to 12.
- 12 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.